Developer docs
API playgroundTry for free, no card

Search company profiles

Full-Life Technologies

Full company profile

uuid00003ft

Namestring
Full-Life Technologies
Legal namestring
Shanghai Full-Life Technologies Co., Ltd. (上海辐联医药科技有限公司)
Websiteurl
full-life.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Full-Life Technologies is a clinical-stage radiotherapeutics company founded in August 2021 and headquartered across Belgium and Shanghai, with additional operations in Germany and the United States. The company focuses on developing targeted radiopharmaceuticals using both alpha-emitting (actinium-225) and beta-emitting (lutetium-177) radionuclides conjugated to tumor-targeting ligands for oncology indications. Its discovery engine, UniRDC™, combines the Clear-X™ linker chemistry toolkit with the Res-X™ radionuclide integration toolkit, complemented by a peptide-based targeting platform acquired through the November 2022 acquisition of Focus-X Therapeutics.

The company operates a five-asset pipeline spanning prostate cancer (lead 225Ac-FL-020, currently Phase 1 with FDA Fast Track Designation), NTSR1 (FL-091, licensed to SK Biopharmaceuticals in a deal worth up to $571.5 million), SSTR2 (FL-031), c-MET (FL-261), and B7H3 (FL-801/FL-802). To secure its radionuclide supply chain and reduce dependence on third-party CDMOs, Full-Life is constructing a GMP-compliant manufacturing facility in Gembloux, Belgium, under a Belgium nuclear permit.

The business model is pre-commercial and relies on a combination of venture capital financing (~USD 200 million raised across five rounds from Chengwei Capital, Sequoia China, Prosperity7, Junson Capital, and Vivo Capital) and partnership-based monetization through licensing agreements. The SK Biopharmaceuticals transaction is the primary external revenue channel via upfront and milestone payments, with future revenue contingent on commercialization of partnered assets. Ultimate commercial value will depend on successful Phase 1 progression of 225Ac-FL-020, regulatory approval pathways, and execution of additional licensing or co-development partnerships.

Short descriptiontext

Full-Life Technologies is a clinical-stage radiotherapeutics company developing alpha- and beta-emitting radiopharmaceutical conjugates for solid tumors, leveraging its UniRDC™ discovery platform and an in-house GMP manufacturing facility to serve oncology patients globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersIsnes, Belgium
HQ citystring
Isnes
HQ countrystring
Belgium
HQ regionstring
Europe
Markets served

Serves global market

Offices7 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
radiopharmaceutical development, radionuclide drug conjugates, cancer therapy pipeline, radiotherapy manufacturing, biotech drug discovery
Industry2 codes
PRIMARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAC
Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Radiopharmaceuticals
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing & Royalty Income (Out-Licensing)
TypeLicensing Royalties
Description

Pre-commercial but secured a major out-licensing deal in July 2024: exclusive worldwide license to SK Biopharmaceuticals for FL-091 (now SKL35501/SKL35502), a NTSR1-targeting alpha-emitter RDC program, with a total deal value of $571.5 million (upfront, development and commercial milestones) plus royalties. Includes a right of first negotiation for SK Biopharmaceuticals on other selected RDC programs. Represents the company's first material revenue stream via upfront and milestone payments.

full-life.com
2Future Therapeutic Product Sales
TypeHardware Sales
Description

Long-term, intended commercial revenue from sales of wholly-owned RDC therapeutic products (e.g., 225Ac-FL-020 for mCRPC, 225Ac-FL-261 for solid tumors) once approved. Company explicitly states it aims to own the entire value chain for radiopharmaceutical research & development, production & commercialization. Currently no products are approved or generating commercial sales revenue.

full-life.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1UniRDC™
Description

Proprietary discovery platform that rationalizes and accelerates the discovery process of RDC (Radionuclide Drug Conjugate) drug candidates, enabling a discovery timeline of 18 months or less from a target to an RDC development candidate.

full-life.com
+2 more records
Core offering1 text field

Full-Life Technologies is a fully integrated global radiotherapeutics company that develops, manufactures, and commercializes Radionuclide Drug Conjugate (RDC) medicines for cancer therapy. Its proprietary UniRDC™ discovery platform uses Clear-X™ linker and Res-X™ modification technologies to generate RDC candidates across small molecule, cyclic peptide, and nanobody modalities. The pipeline includes clinical-stage 225Ac-FL-020 (PSMA), out-licensed FL-091 (NTSR1, now SKL35501/SKL35502), and preclinical candidates FL-031 (SSTR2), FL-261 (c-MET), FL-801 and FL-802 (B7H3), supported by an in-house GMP radiopharmaceutical manufacturing facility in Gembloux, Belgium.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • UniRDC™ platform enables discovery-to-development-candidate timeline of 18 months or less (with human biodistribution data)
+6 more records
Product overview1 text field

Full-Life Technologies is a clinical-stage, fully integrated global radiotherapeutics company with operations in Belgium, Germany and China. Its offering is a platform-plus-modules architecture anchored on the proprietary UniRDC™ discovery platform, which uses the Clear-X™ linker technology and Res-X™ modification methods to generate Radionuclide Drug Conjugate (RDC) candidates spanning small molecules, cyclic peptides, and nanobodies. The pipeline produced from UniRDC™ includes the clinical-stage PSMA-targeting 225Ac-FL-020, the licensed NTSR1 program FL-091 (now SKL35501/SKL35502 at SK Biopharmaceuticals), and preclinical assets FL-031 (SSTR2), FL-261 (c-MET), FL-801 and FL-802 (B7H3). The platform is paired with a GMP-compliant radiopharmaceutical manufacturing facility under construction in Gembloux, Belgium, a global radioisotope production and logistics capability, and a partnering program offering strategic collaborations, platform discovery partnerships, and in-licensing. Together the UniRDC™ discovery engine, pipeline of RDC product candidates and integrated manufacturing/logistics form an end-to-end radiopharmaceutical value chain.

Product and service7 records
1225Ac-FL-020 (PSMA RDC)
CategoryClinical-stage radiopharmaceutical product candidate
2FL-091 (NTSR1 RDC; out-licensed as SKL35501)
CategoryClinical-stage radiopharmaceutical product candidate (licensed)
3FL-031 (SSTR2 RDC)
CategoryPreclinical radiopharmaceutical product candidate
4FL-261 (c-MET RDC)
CategoryPreclinical radiopharmaceutical product candidate
5FL-801 (B7H3 nanobody RDC)
CategoryPreclinical radiopharmaceutical product candidate
6FL-802 (B7H3 RDC)
CategoryPreclinical radiopharmaceutical product candidate
7UniRDC™ Discovery Platform
Scale indicator17 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1SK Biopharmaceuticals
Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-07-01
Description

In July 2024, Full-Life entered an exclusive worldwide licensing agreement with SK Biopharmaceuticals for FL-091 (renamed SKL35501 therapeutic and SKL35502 imaging agent) — a NTSR1-targeting alpha-emitter RDC program. Total deal value of US$571.5 million including upfront payment, development and commercial milestones, and royalties. SK Biopharmaceuticals obtained right of first negotiation for other selected RDC programs from Full-Life. Therapeutic candidate SKL35501 received FDA IND clearance in January 2026 (approximately 18 months after in-licensing), validating Full-Life's UniRDC™ platform.

full-life.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Entered an Actinium-225 (Ac-225) supply agreement with Full-Life Technologies (January 2024) for next generation radiopharmaceuticals. Eckert & Ziegler (ISIN DE0005659700, SDAX-listed) is a German radioisotope and radiopharmaceutical supplier. The agreement supports Full-Life's clinical-stage and pipeline programs targeting the global Ac-225 supply bottleneck.

3Focus-X Therapeutics
Strategic tierFlagshipTypeOthersAnnounced on2022-11-01
Description

Full-Life acquired New Jersey-based Focus-X Therapeutics in November 2022 (close expected Q1 2023) for an upfront payment plus potential development, regulatory and sales-based milestones of up to US$245 million, plus royalties on commercial sales. Acquisition added two development-ready compounds (a PSMA-targeted peptide for mCRPC and a NTSR1-targeted peptide for pancreatic cancer), a proprietary peptide engineering discovery platform, and six earlier-stage programs. Focus-X co-founder Fa Liu became Full-Life's Chief Scientific Officer.

full-life.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Novartis owns Pluvicto (177Lu-PSMA-617) and Lutathera (177Lu-DOTATATE), the two approved radioligand therapies addressing Full-Life's lead PSMA and adjacent SSTR2 indications. Acquired Advanced Accelerator Applications in 2018 and is investing heavily in next-generation alpha-emitter RDCs, making it the dominant incumbent against which Full-Life's 225Ac-FL-020 must compete.

TypeBroad incumbent
Description

Lantheus is a US radiopharmaceutical specialist commercializing diagnostic radiopharmaceuticals (e.g., PYLARIFY for PSMA imaging) and developing PSMA-targeted therapeutics. Acquired Point Biopharma in 2024 to add radioligand therapy capabilities, making it a direct commercial-scale competitor in PSMA.

TypeDirect peer
Description

Telix is a commercial-stage radiopharmaceutical company with approved PSMA-PET imaging agent Illuccix and an emerging therapeutic pipeline, including alpha-emitter programs. Directly comparable to Full-Life as a radiopharma company operating across PSMA imaging and therapy with both diagnostic and therapeutic assets.

TypeBroad incumbent
Description

Bayer markets Xofigo (radium-223) for prostate cancer and acquired Algeta for alpha-emitter therapy. Bayer's broader pharma pipeline and global oncology commercial footprint make it a competitor in alpha-emitter oncology, though its radiopharma focus is narrower than Full-Life's RDC platform.

TypeBroad incumbent
Description

Eli Lilly acquired RayzeBio (actinium-225 RDC platform) in 2024 for $8.7B and Point Biopharma (PSMA-targeted therapy) in 2023, consolidating two leading radiopharmaceutical competitors. Lilly's scale, oncology commercial reach, and big-pharma R&D make it one of Full-Life's most consequential competitors in alpha-emitter RDCs and PSMA.

TypeDirect peer
Description

ITM is a German-based radiopharmaceutical company producing medical radioisotopes and developing targeted radionuclide therapies, including Lu-177 and Ac-225-based candidates. Direct competitor in alpha-emitter RDC development with proprietary isotope production capabilities analogous to Full-Life's Belgium facility.

TypeDirect peer
Description

Ariceum is a private clinical-stage radiopharmaceutical company developing targeted radionuclide therapies (e.g., satoreotide for SSTR2-expressing tumors). Direct comparable to Full-Life in pipeline breadth across multiple solid tumor targets using proprietary peptide-based RDC technology.

TypeEmerging player
Description

Aktis Oncology is a US-based clinical-stage radiopharmaceutical company developing alpha-emitter RDC candidates against validated solid tumor targets, including NTSR1. Direct emerging competitor with overlapping modality (Ac-225 conjugates) and some shared target space with Full-Life's pipeline.

TypeEmerging player
Description

Convergent is developing CLR 131 (radiopharmaceutical) and other targeted radiotherapeutics for prostate cancer. An emerging player in PSMA radioligand therapy overlapping with Full-Life's 225Ac-FL-020 program, focused on next-generation radioconjugates.

TypeOthers
Description

Eckert & Ziegler is a SDAX-listed German radioisotope and radiopharmaceutical supplier that signed an Ac-225 supply agreement with Full-Life in January 2024. Functions as both a strategic supplier and ecosystem participant in the alpha-emitter radiopharmaceutical space, with adjacent (not directly competing) business in isotope production.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors20 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Full-Life Technologies

Radiopharmaceuticalsfull-life.com

Full-Life Technologies is a clinical-stage radiotherapeutics company developing alpha- and beta-emitting radiopharmaceutical conjugates for solid tumors, leveraging its UniRDC™ discovery platform and an in-house GMP manufacturing facility to serve oncology patients globally.

What Full-Life Technologies does

Full-Life Technologies is a clinical-stage radiotherapeutics company founded in August 2021 and headquartered across Belgium and Shanghai, with additional operations in Germany and the United States. The company focuses on developing targeted radiopharmaceuticals using both alpha-emitting (actinium-225) and beta-emitting (lutetium-177) radionuclides conjugated to tumor-targeting ligands for oncology indications. Its discovery engine, UniRDC™, combines the Clear-X™ linker chemistry toolkit with the Res-X™ radionuclide integration toolkit, complemented by a peptide-based targeting platform acquired through the November 2022 acquisition of Focus-X Therapeutics.

The company operates a five-asset pipeline spanning prostate cancer (lead 225Ac-FL-020, currently Phase 1 with FDA Fast Track Designation), NTSR1 (FL-091, licensed to SK Biopharmaceuticals in a deal worth up to $571.5 million), SSTR2 (FL-031), c-MET (FL-261), and B7H3 (FL-801/FL-802). To secure its radionuclide supply chain and reduce dependence on third-party CDMOs, Full-Life is constructing a GMP-compliant manufacturing facility in Gembloux, Belgium, under a Belgium nuclear permit.

The business model is pre-commercial and relies on a combination of venture capital financing (~USD 200 million raised across five rounds from Chengwei Capital, Sequoia China, Prosperity7, Junson Capital, and Vivo Capital) and partnership-based monetization through licensing agreements. The SK Biopharmaceuticals transaction is the primary external revenue channel via upfront and milestone payments, with future revenue contingent on commercialization of partnered assets. Ultimate commercial value will depend on successful Phase 1 progression of 225Ac-FL-020, regulatory approval pathways, and execution of additional licensing or co-development partnerships.

Full-Life Technologies firmographics

Firmographics
Name
Full-Life Technologies
Legal name
Shanghai Full-Life Technologies Co., Ltd. (上海辐联医药科技有限公司)
Website
https://full-life.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
51–100 employees
Short description
Full-Life Technologies is a clinical-stage radiotherapeutics company developing alpha- and beta-emitting radiopharmaceutical conjugates for solid tumors, leveraging its UniRDC™ discovery platform and an in-house GMP manufacturing facility to serve oncology patients globally.
Ownership category
akta.pro rank

Full-Life Technologies industry classification

Industry
Product category
Radiopharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAC
Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine

Keywords

  • Radiopharmaceutical development
  • Radionuclide drug conjugates
  • Cancer therapy pipeline
  • Radiotherapy manufacturing
  • Biotech drug discovery

Where Full-Life Technologies is headquartered

Location

Headquarters

HQ city
Isnes
HQ country
Belgium
HQ region
Europe

Offices7 records

Markets served

Full-Life Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Licensing & Royalty Income (Out-Licensing): Pre-commercial but secured a major out-licensing deal in July 2024: exclusive worldwide license to SK Biopharmaceuticals for FL-091 (now SKL35501/SKL35502), a NTSR1-targeting alpha-emitter RDC program, with a total deal value of $571.5 million (upfront, development and commercial milestones) plus royalties. Includes a right of first negotiation for SK Biopharmaceuticals on other selected RDC programs. Represents the company's first material revenue stream via upfront and milestone payments.
  2. Future Therapeutic Product Sales: Long-term, intended commercial revenue from sales of wholly-owned RDC therapeutic products (e.g., 225Ac-FL-020 for mCRPC, 225Ac-FL-261 for solid tumors) once approved. Company explicitly states it aims to own the entire value chain for radiopharmaceutical research & development, production & commercialization. Currently no products are approved or generating commercial sales revenue.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Full-Life Technologies product offering

Product offering

Core offering

Full-Life Technologies is a fully integrated global radiotherapeutics company that develops, manufactures, and commercializes Radionuclide Drug Conjugate (RDC) medicines for cancer therapy. Its proprietary UniRDC™ discovery platform uses Clear-X™ linker and Res-X™ modification technologies to generate RDC candidates across small molecule, cyclic peptide, and nanobody modalities. The pipeline includes clinical-stage 225Ac-FL-020 (PSMA), out-licensed FL-091 (NTSR1, now SKL35501/SKL35502), and preclinical candidates FL-031 (SSTR2), FL-261 (c-MET), FL-801 and FL-802 (B7H3), supported by an in-house GMP radiopharmaceutical manufacturing facility in Gembloux, Belgium.

Product overview

Full-Life Technologies is a clinical-stage, fully integrated global radiotherapeutics company with operations in Belgium, Germany and China. Its offering is a platform-plus-modules architecture anchored on the proprietary UniRDC™ discovery platform, which uses the Clear-X™ linker technology and Res-X™ modification methods to generate Radionuclide Drug Conjugate (RDC) candidates spanning small molecules, cyclic peptides, and nanobodies. The pipeline produced from UniRDC™ includes the clinical-stage PSMA-targeting 225Ac-FL-020, the licensed NTSR1 program FL-091 (now SKL35501/SKL35502 at SK Biopharmaceuticals), and preclinical assets FL-031 (SSTR2), FL-261 (c-MET), FL-801 and FL-802 (B7H3). The platform is paired with a GMP-compliant radiopharmaceutical manufacturing facility under construction in Gembloux, Belgium, a global radioisotope production and logistics capability, and a partnering program offering strategic collaborations, platform discovery partnerships, and in-licensing. Together the UniRDC™ discovery engine, pipeline of RDC product candidates and integrated manufacturing/logistics form an end-to-end radiopharmaceutical value chain.

Differentiator

Problem solved

Functional benefit

Brands

  • UniRDC™: Proprietary discovery platform that rationalizes and accelerates the discovery process of RDC (Radionuclide Drug Conjugate) drug candidates, enabling a discovery timeline of 18 months or less from a target to an RDC development candidate.
  • Clear-X™
  • Res-X™

Products and services

  • 225Ac-FL-020 (PSMA RDC)
  • FL-091 (NTSR1 RDC; out-licensed as SKL35501)
  • FL-031 (SSTR2 RDC)
  • FL-261 (c-MET RDC)
  • FL-801 (B7H3 nanobody RDC)
  • FL-802 (B7H3 RDC)
  • UniRDC™ Discovery Platform

Quantifiable outcome

  • UniRDC™ platform enables discovery-to-development-candidate timeline of 18 months or less (with human biodistribution data)
  • +6 more outcomes

Companies that use Full-Life Technologies

Customer profile

Segments6 records

Ideal customer profiles1 record

Full-Life Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Full-Life Technologies partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered flagship and core.

  • SK BiopharmaceuticalsflagshipOEM/ Whitelabel/ Licensing Partner · 1 July 2024In July 2024, Full-Life entered an exclusive worldwide licensing agreement with SK Biopharmaceuticals for FL-091 (renamed SKL35501 therapeutic and SKL35502 imaging agent) — a NTSR1-targeting alpha-emitter RDC program. Total deal value of US$571.5 million including upfront payment, development and commercial milestones, and royalties. SK Biopharmaceuticals obtained right of first negotiation for other selected RDC programs from Full-Life. Therapeutic candidate SKL35501 received FDA IND clearance in January 2026 (approximately 18 months after in-licensing), validating Full-Life's UniRDC™ platform.
  • Eckert & ZieglercoreStrategic or Co-development Partner · 1 January 2024Entered an Actinium-225 (Ac-225) supply agreement with Full-Life Technologies (January 2024) for next generation radiopharmaceuticals. Eckert & Ziegler (ISIN DE0005659700, SDAX-listed) is a German radioisotope and radiopharmaceutical supplier. The agreement supports Full-Life's clinical-stage and pipeline programs targeting the global Ac-225 supply bottleneck.
  • Focus-X TherapeuticsflagshipOthers · 1 November 2022Full-Life acquired New Jersey-based Focus-X Therapeutics in November 2022 (close expected Q1 2023) for an upfront payment plus potential development, regulatory and sales-based milestones of up to US$245 million, plus royalties on commercial sales. Acquisition added two development-ready compounds (a PSMA-targeted peptide for mCRPC and a NTSR1-targeted peptide for pancreatic cancer), a proprietary peptide engineering discovery platform, and six earlier-stage programs. Focus-X co-founder Fa Liu became Full-Life's Chief Scientific Officer.

Scale indicators17 records

Recent moves8 records

Expansion highlights6 records

Full-Life Technologies competitors and assessment

Company assessment

Broad incumbents

  • Novartis: Novartis owns Pluvicto (177Lu-PSMA-617) and Lutathera (177Lu-DOTATATE), the two approved radioligand therapies addressing Full-Life's lead PSMA and adjacent SSTR2 indications. Acquired Advanced Accelerator Applications in 2018 and is investing heavily in next-generation alpha-emitter RDCs, making it the dominant incumbent against which Full-Life's 225Ac-FL-020 must compete.
  • Lantheus Holdings: Lantheus is a US radiopharmaceutical specialist commercializing diagnostic radiopharmaceuticals (e.g., PYLARIFY for PSMA imaging) and developing PSMA-targeted therapeutics. Acquired Point Biopharma in 2024 to add radioligand therapy capabilities, making it a direct commercial-scale competitor in PSMA.
  • Bayer: Bayer markets Xofigo (radium-223) for prostate cancer and acquired Algeta for alpha-emitter therapy. Bayer's broader pharma pipeline and global oncology commercial footprint make it a competitor in alpha-emitter oncology, though its radiopharma focus is narrower than Full-Life's RDC platform.
  • Eli Lilly (RayzeBio / Point Biopharma): Eli Lilly acquired RayzeBio (actinium-225 RDC platform) in 2024 for $8.7B and Point Biopharma (PSMA-targeted therapy) in 2023, consolidating two leading radiopharmaceutical competitors. Lilly's scale, oncology commercial reach, and big-pharma R&D make it one of Full-Life's most consequential competitors in alpha-emitter RDCs and PSMA.

Direct peers

  • Telix Pharmaceuticals: Telix is a commercial-stage radiopharmaceutical company with approved PSMA-PET imaging agent Illuccix and an emerging therapeutic pipeline, including alpha-emitter programs. Directly comparable to Full-Life as a radiopharma company operating across PSMA imaging and therapy with both diagnostic and therapeutic assets.
  • ITM Isotope Technologies Munich SE: ITM is a German-based radiopharmaceutical company producing medical radioisotopes and developing targeted radionuclide therapies, including Lu-177 and Ac-225-based candidates. Direct competitor in alpha-emitter RDC development with proprietary isotope production capabilities analogous to Full-Life's Belgium facility.
  • Ariceum Therapeutics: Ariceum is a private clinical-stage radiopharmaceutical company developing targeted radionuclide therapies (e.g., satoreotide for SSTR2-expressing tumors). Direct comparable to Full-Life in pipeline breadth across multiple solid tumor targets using proprietary peptide-based RDC technology.

Emerging players

  • Aktis Oncology: Aktis Oncology is a US-based clinical-stage radiopharmaceutical company developing alpha-emitter RDC candidates against validated solid tumor targets, including NTSR1. Direct emerging competitor with overlapping modality (Ac-225 conjugates) and some shared target space with Full-Life's pipeline.
  • Convergent Therapeutics: Convergent is developing CLR 131 (radiopharmaceutical) and other targeted radiotherapeutics for prostate cancer. An emerging player in PSMA radioligand therapy overlapping with Full-Life's 225Ac-FL-020 program, focused on next-generation radioconjugates.

Others

  • Eckert & Ziegler: Eckert & Ziegler is a SDAX-listed German radioisotope and radiopharmaceutical supplier that signed an Ac-225 supply agreement with Full-Life in January 2024. Functions as both a strategic supplier and ecosystem participant in the alpha-emitter radiopharmaceutical space, with adjacent (not directly competing) business in isotope production.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Full-Life Technologies social profiles

Digital presence

Full-Life Technologies compliance and trust

Trust signal

Compliance4 records

Full-Life Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Full-Life Technologies leadership team

Management profile

Number of profiles

Profiles8 records

Full-Life Technologies subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Full-Life Technologies funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors20 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Full-Life Technologies M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Full-Life Technologies

What does Full-Life Technologies do?

Full-Life Technologies is a fully integrated global radiotherapeutics company that develops, manufactures, and commercializes Radionuclide Drug Conjugate (RDC) medicines for cancer therapy. Its proprietary UniRDC™ discovery platform uses Clear-X™ linker and Res-X™ modification technologies to generate RDC candidates across small molecule, cyclic peptide, and nanobody modalities. The pipeline includes clinical-stage 225Ac-FL-020 (PSMA), out-licensed FL-091 (NTSR1, now SKL35501/SKL35502), and preclinical candidates FL-031 (SSTR2), FL-261 (c-MET), FL-801 and FL-802 (B7H3), supported by an in-house GMP radiopharmaceutical manufacturing facility in Gembloux, Belgium.

Is Full-Life Technologies a public or private company?

Full-Life Technologies is a private company. It is classified as venture growth investor backed and is currently operating.

When was Full-Life Technologies founded?

Full-Life Technologies was founded in 2021. It employs 51 to 100 people.

Where is Full-Life Technologies based?

Full-Life Technologies is headquartered in Isnes, Belgium, in the Europe region.

How does Full-Life Technologies make money?

Two revenue lines are on record. Licensing & Royalty Income (Out-Licensing) is the primary driver. The others are future Therapeutic Product Sales.

Who are Full-Life Technologies's main competitors?

Broad incumbents on record are Novartis, Lantheus Holdings, Bayer and Eli Lilly (RayzeBio / Point Biopharma). Direct peers are Telix Pharmaceuticals, ITM Isotope Technologies Munich SE and Ariceum Therapeutics. Emerging players are Aktis Oncology and Convergent Therapeutics. Eckert & Ziegler is listed as an others.

Does Full-Life Technologies have an API?

No public API is recorded for Full-Life Technologies.

What industry is Full-Life Technologies in?

Full-Life Technologies's product category is Radiopharmaceuticals. Its primary akta.pro industry code is HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy), with a secondary code of HLAIAGAC, Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PRESSBEEFull-Life Technologies Reports Encouraging Preliminary Phase 1 Safety and PSA Decline for FL-020 in mCRPC at ESMO 2026 ...Middle EastFull-Life Technologies presented preliminary Phase 1 data for FL-020 in metastatic castration-resistant prostate cancer at ESMO 2026, showing no dose-limiting toxicities and predominantly Grade 1 xerostomia. All lutetium-177-naive patients achieved PSA50, with 88.9% of all patients responding.PR NewswireFull-Life Technologies Reports Encouraging Preliminary Phase 1 Safety and PSA Decline for FL-020 in mCRPC at ESMO 2026Full-Life Technologies presented preliminary Phase 1 data on [225Ac]Ac-FL-020 for mCRPC at ESMO 2026, showing PSA declines in both lutetium-177-naive and -exposed patients. At dose levels 6-8 MBq, 100% of naive patients achieved PSA50, while 75% of exposed patients did. A Phase 2 dose optimization study is planned.PR NewswireFull-Life Technologies Reports First-in-Human Imaging Data for c-MET-Targeting Theranostic Ligand FL-261 Showing Robust Tumor Uptake, High Lesion Contrast and No Tracer-Related Serious Adverse EventsFull-Life Technologies presented first-in-human imaging data for its c-MET-targeting theranostic ligand FL-261 at the EANM Congress, showing robust tumor uptake and high lesion contrast in 10 non-small cell lung cancer patients. The data reported no tracer-related serious adverse events and uptake that rose with c-MET expression, supporting the advancement of [225Ac]Ac-FL-261 into Phase 1 trials.BioWorldFull-Life’s [225Ac]Ac-FL-261 cleared for clinic in US, AustraliaFull-Life Technologies Ltd. obtained regulatory clearances in the U.S. and Australia for a first-in-human phase I trial of [225Ac]Ac-FL-261 in patients with c-MET-expressing non-squamous non-small-cell lung cancer. The trial is a phase I study, and the clearances were granted in both countries.PR Newswire APACFull-Life Technologies Announces U.S. FDA IND Clearance and Australian Regulatory Clearance for [²²⁵Ac]Ac-FL-261 Phase 1 Clinical TrialFull-Life Technologies received FDA IND clearance and Australian HREC/TGA approval for its [225Ac]Ac-FL-261 Phase 1 trial in c-MET-expressing non-squamous non-small cell lung cancer. The trial will assess safety, tolerability, pharmacokinetics, and preliminary antitumor activity. The company plans to conduct clinical development in the U.S., Australia, and other key regions.BioSpaceFull-Life Technologies Announces U.S. FDA IND Clearance and Australian Regulatory Clearance for [²²⁵Ac]Ac-FL-261 Phase 1 Clinical TrialFull-Life Technologies received FDA IND clearance and Australian HREC/TGA approval for its [225Ac]Ac-FL-261 Phase 1 trial in c-MET-expressing non-squamous non-small cell lung cancer. The trial will assess safety, tolerability, pharmacokinetics, and preliminary antitumor activity. The company plans to conduct clinical development in the U.S., Australia, and other key regions.Stock TitanActinium names Steffen Heeger CMO for radiotherapyActinium Pharmaceuticals appointed Steffen Heeger, MD, MSc, as Chief Medical Officer on June 1, 2026, bringing over two decades of oncology and radiotherapy development experience including leading Erbitux to blockbuster status at Merck KGaA and serving as CMO of NBE Therapeutics, which was acquired by Boehringer Ingelheim for $1.4 billion. Dr. Heeger most recently served as CMO of Full-Life Technologies, where he advanced anti-PSMA radioconjugate programs into clinical development within two years, securing IND clearance and fast-track designation. The appointment is positioned to accelerate Actinium's pipeline of targeted radiotherapies including Actimab-A, ATNM-400, and Iomab-ACT toward key data readouts and expanded clinical trials in the second half of 2026.BioWorldFinancings for May 26, 2026On May 26, 2026, biopharma and med-tech companies in Asia-Pacific raised funds through public or private financings. The companies named are Accro, Forlong, and Full-Life Technologies.InvestorsinhealthcareBelgium: Full-Life Technologies raises US$150m to advance clinical stage assetsFull-Life Technologies, a clinical stage radiotherapeutics company, raised US$150m led by Vivo Capital. The financing package was announced, with Vivo joining the round. The company operates in Belgium, Germany, and China.Pulse 2.0Full-Life Technologies: $150 Million Financing To Advance Clinical-Stage Radiotherapeutics Pipeline And Manufacturing CapabilitiesFull-Life Technologies announced the completion of a US$150 million financing package, comprising approximately US$110 million in Series D equity and US$40 million in debt, led by Vivo Capital with participation from strategic partner SK Biopharmaceuticals and multiple other investors. The funding will advance the company's clinical-stage radiotherapeutics pipeline, including [225Ac]-FL-020 for prostate cancer and [225Ac]-FL-261 for solid tumors, with a goal of having three differentiated clinical-stage programs by end of 2026. The proceeds will also support the launch of GMP-grade 225Ac manufacturing operations at Full-Life's facility in Belgium, providing internal control over isotope supply and manufacturing.